Proteomic assessment of SKBR3/HER2+ breast cancer cellular response to Lapatinib and investigational Ipatasertib kinase inhibitors
Altogether, the exposure of SKBR3/HER2+ cells to Lapatinib and Ipatasertib kinase inhibitors uncovered a broad plethora of yet untapped opportunities that can be further explored for enhancing the anti-cancer effects of each drug as well as of many other multi-drug therapies that target the EGFR/ERBB2 and PI3K/AKT pathways.
Authors
- Iulia M. Lazar (ORCID: https://orcid.org/0000-0001-7746-7889)
- Arba Karcini (ORCID: https://orcid.org/0000-0003-2511-228X)
- Nicole R. Mercier
Institutions
- Carilion Clinic (US)
- Virginia Tech (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.3389/fphar.2024.1413818
- Citations
- 3
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.08
Funders
- National Institute of General Medical Sciences